Evidence map›Paper›PMID 38044946›Full record

ArticleFrontiers in pharmacology2023

Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteers.

Xiaojiao Li, Min Wu, Jixuan Sun, Weili Jin, Lei Han, Jia Xu, Jingrui Liu, Hong Zhang, Jing Wang, Daidi Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiaojiao LiPhase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, China.
Min WuPhase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, China.
Jixuan SunPhase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, China.
Weili JinXi'an Xintong Pharmaceutical Research Co., Ltd., Xi'an, China.
Lei HanXi'an Xintong Pharmaceutical Research Co., Ltd., Xi'an, China.
Jia XuPhase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, China.
Jingrui LiuPhase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, China.
Hong ZhangPhase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, China.
Jing WangPhase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, China.
Daidi WangXi'an Xintong Pharmaceutical Research Co., Ltd., Xi'an, China.
Hanyi ZhangXi'an Xintong Pharmaceutical Research Co., Ltd., Xi'an, China.
Qing ZhangXi'an Xintong Pharmaceutical Research Co., Ltd., Xi'an, China.
Nini LiuXi'an Xintong Pharmaceutical Research Co., Ltd., Xi'an, China.
Yanhua DingPhase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CE-fosphenytoin sodiumfosphenytoin sodiumhealthy volunteerspharmacokineticssafety

Identifiers

PMID38044946
PMCPMC10691362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.